Abstract
INTRODUCTION
A major limitation of endoscopic ultrasound (EUS) examination is its limited capacity to determine the exact nature of a lesion. Differential diagnosis between benign and malignant lymph nodes and focal pancreatic masses . Elastography has recently been presented as a novel examination to assess and measure tissue elasticity. Knowing that malignant tissues are generally harder than normal surrounding tissue, elastography might provide interesting clinical information to help distinguish benign from malignant tissue based on their specific tissue consistency. Clinical research has shown promising results in differentiating between benign and malignant tissue in the thyroid gland , breast , prostate and to assess liver fibrosis . Recently, elastography has also been introduced during EUS examination . The cur rent study is a continuation of previous research to validate the potential role of elastography in distinguishing benign from malignant lymph nodes and focal pancreatic lesions in a large retrospective trial. The aim of this multicenter study was to classify lymph nodes and pancreatic masses during EUS examination as elastography patterns and to compare the results with a
MATERIALS AND METHODS

Patients, procedure and examination technique
Every patient (n = 222) who underwent EUS examination with evaluation of a pancreatic mass (n =121) or lymph nodes (n 2007, was included. The study was conducted in seven different centers throughout Europe. Only one lesion per patient was examined and by one single endoscopist per center. Each center started the study after six months experience of EUS elastography. The EUS examinations were performed with conventional linear EUS probes Germany). The examined lesion was first classified as in real time using a commercially available module Medical Systems Europe, Zug, Switzerland). The technology measures the degree of tissue deformation after compression as an indicator for the stiffness of tissue. This compression during EUS examination is naturally obtained by arterial pulsations and respiratory movements. Detailed reviews on the technical aspects of elastography have been previously published . The sample area was adjusted to the region of interest and the suitability of the elastographic signal was indicated by a numeric scale within the image. Tissue elasticity areas were marked with blue, intermediate areas with green, medium soft areas with yellow and soft areas with simultaneously side by side. The complete spectrum from blue to red was applied to each elastographic image and represented the graduation of relative elasticity within the sample area. Elastographic images were interpreted during the examination and a 60 s video loop was recorded for an interobserver study.
was performed in all cases for clinical reasons using described elsewhere . In all participating centers, the specimen were examined using the monolayer cytology only four centers during the examination. In the the remaining centers, the endoscopist assessed the sample to ensure sufficient tissue was obtained based on the and repeat punctures were performed if necessary. The pathologist was blinded to the elastography results. The was carried out in the absence of surgical specimens. The following parameters were recorded in a protocol: the classification as benign or malignant based on the on histology.
Scoring system
The elastographic images were scored according to elastographic patterns based on previous research : a a homogenous soft tissue area (green) corresponding image indicated heterogenous soft tissue (green, yellow, classify as benign or malignant based on the elastographic
Statistical analysis
The results are presented as means plus or minus standard deviation or as medians with ranges, depending and accuracy were calculated as appropriate.
An interobser ver study was perfor med on a statistically representative and blinded selection of 30 videos (15 of a pancreatic mass and 15 of a lymph node). These videos were each evaluated by five endoscopists experienced in EUS and elastography. The elastographic images were scored with a whole number from 1 to 5 using the previous described criteria, constituting an ordered variable. The agreement between two different examiners was measured by an adapted kappa coefficient. The interobserver study also evaluated the agreement between two examiners to classify the examined tissue as benign or malignant. The result is a binary variable ("malignant" or "benign"). The results being "inconclusive" were considered as missing data for the calculation of the agreement. This agreement was measured by the Cohen
RESULTS
Pancreatic masses
mean age 63 years) underwent EUS examination with elastography for evaluation of a pancreatic mass (mean located in the pancreatic head (n n = 17), body (n = 29), tail (n = 13) and uncinate process (n diagnosis of the pancreatic masses included pancreatic adenocarcinoma (n = 72), malignant endocrine tumor (n = 16), benign endocrine tumor (n = 2), benign chronic pancreatitis related nodules (n metastasis (n were interpreted as benign (score 1 + 2 = A) in 31 cases, indeterminate (score 3 = B) in 19 cases and and negative predictive values of EUS elastography to differentiate benign from malignant pancreatic masses calculated sensitivity, specificity, positive and negative differentiate benign from malignant pancreatic masses an accuracy of 71.9% (Table 1) .
Lymph nodes
age 61.1 years) underwent EUS examination of a lymph node for staging of lung cancer (n = 25), oesophageal carcinoma (n = 25), gastric cancer (n = 13), pancreatic cancer (n = 13), for suspicion of lymph node relapse of kidney cancer (n = 2) and of breast cancer (n EUS examination was also performed for evaluation of isolated lymph nodes (n = 15). Lymph nodes (mean mediastinum (n = 51), in the cervical area (n celiac or mesenteric area (n space (n study. The final histological assessment was based on cases, including metastasis of an adenocarcinoma (n = 35), n = 13), metastasis of an endocrine tumor (n = 3), metastasis of a melanoma (n = 1), lymphomas (n = 5), and benign in
The elastographic images were interpreted as benign 50.0%, 70.5% and 60.6% with an accuracy of 67.3% (Table 2) .
Inter-observer study and 0.520 for all cases confound. masses, 0.657 for the lymph nodes and 0.725 for all cases confound. 
DISCUSSION
The aim of this multicenter study was to evaluate the ability of EUS elastography to distinguish benign from malignant focal pancreatic masses and lymph nodes and Our study shows that EUS elastog raphy has high sensitivity, specificity and accuracy and a much to differentiate between benign and malignant focal pancreatic lesions. Using our current scoring system, 15.7% of the cases still obtain an elastography score and we believe that the soft tissue parts of these focal lesions on elastography represent necrotic areas in an adenocarcinoma (n = 15) or a hypervasccularised area in an endocrine tumor (n our opinion.
T h e r e we r e s e ve n f a l s e n e g a t ive c a s e s ( f ive adenocarcinoma and two neuroendocrine tumors) that may be explained in a similar way: the presence of abundant necrotic or vascular tissue resulted in an elastographic pattern mainly consisting of soft tissue. By contrast, the false positive cases in our study (n = 6) might represent patients with (early) chronic pancreatitis Janssen et al , the elastographic patterns of the normal pancreas and the pancreas affected by inflammatory or focal disease were studied. They concluded that elastography does not distinguish between chronic structure. This implies that EUS elastography will not be able to help target suspicious lesions and improve chronic pancreatitis.
In distinguishing benign from malignant focal pancreatic lesions, EUS elastography does not replace should not be used as a first line examination in the of the EUS elastographic images could help orientate the diagnosis and influence the decision making for surgery when the lesion is suspicious on elastography, or favour of a benign lesion.
Our data also shows that EUS elastography has high sensitivity, specificity and accuracy in distinguishing benign from malignant lymph nodes and seems to be false negative and false positive cases in this study are due to the presence of necrotic and fibrotic areas in lymph nodes, respectively, is less certain. Our results et al using similar elastography pattern criteria to differentiate with a reported sensitivity, specificity and accuracy of, elastography to distinguish benign from malignant lymph nodes should be considered as complementary to other might help in selecting more suspicious lymph nodes for tissue sampling, especially in patients presenting multiple lymph nodes, such as in oesophageal or lung cancer.
number of unnecessary biopsies. As for focal pancreatic lesions, EUS elastography might offer an alternative for malignant tissue or interposed vascular structure).
The current results are different from the results obtained during our previous research . In this previous study, EUS elastography was shown to have a sensitivity of 100% and specificities of 67% and 50% for diagnosing malignant pancreatic masses and lymph nodes, respectively. Although false positive results in both study groups were reported, it should be recalled that the number of benign lesions in the previous study was relatively small. elastography might also help in guiding the puncture in a non necrotic part of the suspicious lesion when necrotic tissue is present, as in advanced cancer. One of the main criticisms of EUS elastography is the variability of the elastographic images and the study showed a satisfying interobserver concordance for the differentiation between benign and malignant pancreatic masses and lymph nodes ( = 0.725).
In the absence of pathologic assesment of surgical to 100% of malignancy into lymph nodes or to give false negative consider it as representative of daily practice, particularly
To overcome the difficulty in classifying the EUS malignant, we are currently evaluating the next generation of elastography software. This new software provides a and has already proven to be useful in the evaluation of lymph nodes . The potential role of EUS elastography to help detect and differentiate submucosal tumors as well as any other solid masses situated nearby the gastrointestinal tract has still to be evaluated. The exact role of EUS elastography in patients manifesting symptoms suggestive of chronic still to be validated . the endosonography and seems to be able to differentiate benign from malignant lymph nodes and pancreatic lesions with a high sensitivity, specificity and accuracy. EUS elastography is superior compared to conventional Instead, the information obtained by EUS elastography should be considered as complementar y to the conventional EUS imaging. It should be reserved as a second line examination to orientate further decision the number of unnecessary biopsies when assessing improve our current elastography scoring system. The second generation of elastography software providing
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